



## Depression in 2020, a multidimensional approach? Oxolipidomic profiles in major depressive disorder

### SEMINAR & VISITING SPEAKER SERIES

#### DATE

Friday, October 25, 2019  
9:00AM

#### LOCATION

PX236/238 PsychHealth Building

#### SPEAKER

**Dr. Mandana Modirrousta**  
MD, PhD, FRCPC

Associate Professor  
University of Manitoba,  
Department of Psychiatry | Pathology &  
Pathophysiology

Department of Neurodegenerative  
Disorders, St. Boniface Hospital  
Albrechtsen Research Centre

#### BIO

Dr. Modirrousta is an Associate Professor at the University of Manitoba, Rady Faculty of Health sciences. She is a neuropsychiatrist certified by the United Council of Neurologic Subspecialties. She completed her residency in psychiatry at the University of Manitoba in 2012 before pursuing a fellowship in neuropsychiatry at Massachusetts General Hospital, Harvard Medical School. Prior to her residency, Dr. Modirrousta earned a PhD in neuroscience from the Montreal Neurological Institute at McGill University and completed post-doctoral training in cognitive neuroscience.

For more information:

T: 204-235-3939

E: [Networking@manitobaneuroscience.ca](mailto:Networking@manitobaneuroscience.ca)

#### ABOUT

Dr. Modirrousta uses neuropsychological and neurocognitive tools as well as repetitive transcranial magnetic stimulation (rTMS) to study the link between the brain and behaviour in a variety of neuropsychiatric disorders. In 2010, she received the Association of Chairs of Psychiatry in Canada research award and the American Psychiatric Association award. Most recently, she was awarded the 2019 Helping Hands Award by the Mood Disorder Association of Manitoba. She is on the Board of Directors for the Alzheimer Society of Manitoba. Her clinical interest focuses on patients with cognitive deficit in particular those with Early-Onset Dementia.

#### OBJECTIVES

1. To get familiar with different dimensions and deficits in patients with depression.
2. To discuss the role of biomarkers and technologies in future assessment and treatment of depression.
3. To discuss the results of our recent study of biomarkers in depression.